Canada Libidus warning
This article was originally published in The Tan Sheet
Executive Summary
Using the natural health product Libidus, which contains vardenafil, the same active ingredient contained in GlaxoSmithKiline's/Schering-Plough's Levitra, could pose health risks, especially for people with heart problems, taking heart medications or at risk for stroke, Health Canada announces. Libidus, which is manufactured in Malaysia by Bio-Gulf, contains a modified form of vardenafil, but the substance is not declared on product packages, the Canadian health agency says. Winnipeg, Manitoba-based distributor NorthRegentRX has been contacted and is recalling the product from Canadian markets, the agency says. Results of an FDA survey from earlier this year identified Libidus, and six other supplements as illegal because they contain undeclared non-dietary chemicals similar or equivalent to sildenafil or vardenafil (1"The Tan Sheet" July 17, 2006, p. 4). Products containing vardenafil should not be used by people taking nitrate medication because combining the products could result in dangerously low blood pressure...
You may also be interested in...
FDA Survey Of ED Supplements Shows Contamination With Viagra, Levitra
A "first-of-its-kind" FDA survey of 17 dietary supplements marketed to treat erectile dysfunction revealed that seven of the products are actually illegal drugs due to adulteration with active ingredients used in Rx ED treatments, the agency states in a July 12 release
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.